ClinicalTrials.gg
Not yet recruitingNCT06432855GEDIPOPUpdated Jun 24, 2024

Genetic Determinants of the Antiviral Immune Response in Oceanian Populations

An interventional study of Blood collection and saliva collection in Virus, sponsored by Institut Pasteur. Not yet recruiting at 1 site in New Caledonia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War. In New Caledonia (NC), the incidence of dengue fever is higher among municipalities predominantly populated by Melanesians, suggesting that Melanesians may have an increased susceptibility to symptomatic dengue fever. Differences in antiviral immune responses between populations of different geographical origins are partly the result of population-specific immune regulatory variants. In turn, viruses have imposed considerable selective pressure on human populations. Although crucial to understanding their susceptibility to viral infections, the genetic determinants of the antiviral immune response of Oceanians remain to be characterized.

In this context, the hypothesis is that the genetic origin of Oceanians, and Melanesians in particular, has shaped their antiviral immune response and contributes to their greater susceptibility to certain viral infections. The aim is to characterize the immune response to pathogens affecting the New Caledonian population, and in particular to dengue virus, of Melanesian and European populations, and to identify its genetic determinants. It will be explored whether saliva can be used as a non-invasive sample to study the seroprevalence of dengue in Oceanian populations.

Read the detailed description

Cross-sectional observational study with prospective sample and data collection Individuals will be identified from among eligible participants in the STEP-BSA21 and COVCAL studies.

Information and consent Questionnaire, saliva collection on Oragene tube, buccal swabbing and 20 mL blood collection on CPT tube

DNA extraction and low-coverage sequencing of participants' complete genomes And Isolation and in vitro stimulation of peripheral blood mononuclear cells (PBMCs) with dengue virus

  • single-cell RNA sequencing (scRNAseq)
  • multiplex quantification of cytokines and chemokines
  • bioinformatics analysis to identify genetic markers associated with a differential transcriptomic and secretory response to dengue virus stimulation.
02

Conditions studied

  • Virus

Keywords

  • dengue
  • immunity
  • genetics
  • Ocenian populations
  • New Caledonia
03

In context

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

This study's planned enrollment of 220 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.

Browse Virus Diseases studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult
  • Non-febrile
  • Self-declared member of the Melanesian or European community
  • Having given consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • People who have taken part in a clinical study in the last 6 months in which they were exposed to a health product as part of the investigation (pharmaceutical product or device or placebo).
  • People taking part in an ongoing clinical study
  • People declaring themselves to belong to two communities (e.g. people of mixed European and Melanesian descent)
  • Pregnant and breast-feeding women (in whom the immune response could be modified)
  • People with a long-term medical condition (as defined by the French social security system) that could have an effect on the immune response, excluding dengue risk factors prevalent in New Caledonia such as diabetes, overweight/obesity and hypertension.
  • Individuals with an acute infection (viral, bacterial or fungal) within 3 months of inclusion.
  • Chronic administration (for more than 14 days) of or treatments affecting the immune system in the 6 months prior to inclusion. For , this corresponds to a dose equivalent to 20 mg/day of prednisone or equivalent for more than two weeks (inhaled or topical steroids are permitted).
  • Administration of a vaccine within 3 months prior to inclusion.
  • Administration of blood products or immunoglobulins within 3 months of inclusion.
  • People with known allergies to antibiotics, which could have an impact on the in vitro culture of PBMCs in the presence of antibiotics
  • Persons not intellectually capable of answering the questionnaire
  • Persons under guardianship, curatorship or any other legal incapacity
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Other
    Non-febrile adults of Melanesian and European origin

    Saliva samples and 20 mL blood samples from individuals of Melanesian and European origin from NC

    Other: Blood collection · Other: saliva collection

Interventions

  • OtherBlood collection

    20 ml-blood sample

  • Othersaliva collection

    saliva sample

06

What researchers measure

Primary outcomes

  1. Identify the genetic determinants of the innate immune response to pathogens affecting the New Caledonian population, and in particular to the dengue virus in individuals of Melanesian and European origin.

    Identification by genomic techniques of expression Quantitative Trait Loci (eQTL) specifically associated with the innate immune response of Peripheral Blood Mononuclear Cells (PBMCs) collected from individuals of Melanesian and European origin and stimulated in vitro by DENV.

    Time frame: 3 years

Secondary outcomes

  1. To describe the genetic diversity of Melanesian and European populations in NC in relation to the determinants of susceptibility to health problems affecting NC populations.

    Low-coverage DNA sequencing of the complete genome of individuals of Melanesian and European origin.

    Time frame: 3 years

  2. Characterizing the transcriptomic response to DENV in individuals of Melanesian and European origin.

    Quantification by single cell RNAseq techniques of differentially expressed transcripts in response to in vitro dengue virus stimulation by Peripheral Blood Mononuclear Cells (PBMCs) collected from individuals of Melanesian and European origin.

    Time frame: 3 years

  3. Characterize the cytokine and chemokine response to DENV in individuals of Melanesian and European origin.

    Quantification by multiplex techniques of the concentration of cytokines and chemokines differentially secreted in response to in vitro stimulation by dengue virus by Peripheral Blood Mononuclear Cells (PBMCs) collected from individuals of Melanesian and European origin.

    Time frame: 3 years

  4. Study the effect of environmental factors (smoking/non-smoking status, history of Cytomegalovirus or dengue virus infection, presence of diabetes, etc.) on the immune response to dengue virus.

    Multivariate analyses of the association of environmental factors collected during the inclusion visit (questionnaire and measurements) or during analyses conducted as part of the present research with the immune response targeting the dengue virus.

    Time frame: 3 years

  5. Study the oral microbiome of individuals of Melanesian and European origin and analyze its association with the immune response to pathogens.

    Next-generation sequencing and analysis of the oral microbiome on a saliva sample

    Time frame: 3 years

  6. Determine whether history of dengue virus infection can be demonstrated by testing saliva for antibodies using the Luminex technique.

    Luminex quantification of dengue virus antibodies in serum and saliva from Melanesian and European individuals.

    Time frame: 3 years

07

Study locations

1 site
  • Institut Pasteur de Nouvelle-Calédonie
    Nouméa, 98 835, New Caledonia
    • Marc Jouan, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Jun 2025, 12 months later.

Of 61 interventional studies with no phase under Virus Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 29, 2024
StartEst.
Jun 15, 2024
Primary completionEst.
Jun 15, 2025
CompletionEst.
Dec 15, 2027
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06432855
Lead sponsor
Institut Pasteur
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Jun 15, 2024 (estimated)
Primary completion
Jun 15, 2025 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Jun 24, 2024

Study contacts

Catherine Inizan, PhD
Contact
cinizan@pasteur.nc
+687 27 26 66
Myrielle Dupont-Rouzeyrol, PhD
Contact
mdupont@pasteur.nc
+687 27 75 30
Marc Jouan, MD
principal investigator · Institut Pasteur de Nouvelle-Calédonie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion